General pharmacology PBPK

Pediatric bevacizumab minimal PBPK

Reference paper ↗

A minimal PBPK model connecting body-weight-scaled bevacizumab clearance and compartment volumes to central and peripheral antibody exposure.

Therapeutic
Bevacizumab
Modality
Monoclonal antibody
Target
VEGF-A
Disease
Pediatric-to-adult bevacizumab exposure bridging
Model type
PBPK

Complete model workspace

Checking workspace access…

Parameters
6
States
3
Equations
3
Derived outputs
11

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Female >=18 10 mg/kg every 2 weeks

How does pediatric body weight change bevacizumab compartment volumes, clearance, concentration, and exposure? Explore this intervention regimen through Central bevacizumab concentration, Cumulative bevacizumab exposure, Total bevacizumab clearance, Central distribution volume.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–3,024 hour; step 4

InputDefaultAvailable range
Body weight62 kg31–93 kg
Catabolic clearance0.0175 L/h0.00875–0.02625 L/h
Additional clearance0.00278 L/h0.00139–0.00417 L/h
Central volume0.03812 L/kg0.01906–0.05718 L/kg
Peripheral volume0.02859 L/kg0.01429–0.04288 L/kg

Expected readouts

Central bevacizumab concentration · Exposure (AUC) (mg*h/L) · Total bevacizumab clearance · Central distribution volume

Adjustable model parameters

This public explorer exposes 5 curated parameters. Sign in to edit all 6 declared model parameters.

More key parameters (1)

How the model represents the biology

A minimal PBPK model connecting body-weight-scaled bevacizumab clearance and compartment volumes to central and peripheral antibody exposure.

How do body size, disposition volumes, and clearance shape pediatric bevacizumab exposure?A body-weight-based bevacizumab regimen enters a central pool, exchanges with a peripheral pool, undergoes catabolic plus additional clearance, and accumulates central exposure. Body weight explicitly scales the dose and compartment volumes, not absolute clearance.BIOLOGY OVERVIEWHow do body size, disposition volumes, and clearance shape pediatric bevacizumabexposure?IV bevacizumab10 mg/kg regimen inputBody weightScales dose and volumesCentral exposureWeight-scaled central volumePeripheral poolWeight-scaled distributionvolumeTotal clearanceCatabolic plus additional lossCumulative exposureCentral concentration integralPRIMARY READOUTSCentral bevacizumab concentrationCentral bevacizumab concen…Cumulative exposureCumulative exposureTotal clearanceTotal clearanceCentral volumeCentral volume

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: VEGF binding or pharmacodynamics, organ-resolved PBPK, FcRn trafficking, maturation or ontogeny, and explicit body-weight scaling of absolute clearance are not represented.

Modeled relationships (6)
  • IV bevacizumab → Central exposure: IV input (flow)
  • Central exposure ↔ Peripheral pool: distribution (reversible exchange)
  • Body weight → Central exposure: scales Vc (modulation)
  • Body weight → Peripheral pool: scales Vp (modulation)
  • Central exposure → Total clearance: CLcat + CLadd (loss)
  • Central exposure → Cumulative exposure: integrates C (production)

Modeled relationships: IV bevacizumab to Central exposure: IV input (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Body weight to Central exposure: scales Vc (modulation); Body weight to Peripheral pool: scales Vp (modulation); Central exposure to Total clearance: CLcat + CLadd (loss); Central exposure to Cumulative exposure: integrates C (production).

Primary readouts: Central bevacizumab concentration; Cumulative exposure; Total clearance; Central volume.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID sule_2025_bevacizumab_minimal_pbpk_pediatric_bridge.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics